Activity of sparfloxacin against Mycobacterium leprae inoculated into footpads of nude mice.
The antileprosy activity of a new quinolone, sparfloxacin, was examined in the nude mouse footpad model. By serial dosing (once a day, 5 or 6 times per week, during the 3rd-5th months postinoculation), 10 mg/kg of sparfloxacin displayed bactericidal-type activity and bacteriostatic activity was present at daily doses of 5 and 2 mg/kg. By intermittent dosing (once a day, twice weekly at daily doses of 10 and 20 mg/kg or once weekly at a daily dose of 30 mg/kg, during the 3rd-5th months postinoculation), sparfloxacin markedly inhibited the growth of leprosy bacilli with slight remultiplication at later stages. Sparfloxacin seems to be worth studying clinically as a novel antileprosy drug.
Gidoh
M
M
National Institute for Leprosy Research, Tokyo, Japan.
Tsutsumi
S
S
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D005260:Female; D024841:Fluoroquinolones; D005528:Foot / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000254:growth & development; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C061363:sparfloxacin